欧洲，中东和非洲
智能产生证据的方式
The increasing costs of developing treatments requires smarter approaches. Access a wide spectrum of data and sourcing approaches from existing secondary data, primary data, registry collaborations, and patient reported outcomes.
Every study is different. Tap into our fit-for-purpose study designs. The IQVIA CORE supports specific research needs built on our domain expertise, unparalleled data, transformative technology and advanced analytics.
IQVIA是RWD来源的RWE市场思想和专家，以及适当的使用，RWD分析能力和RWE生成，并具有很大的利润。资料来源 - 生活科学战略集团有限责任公司 - 现实世界证据报告
更智能的研究方法
我们正在通过现在可以利用创新的方法来重新构想证据生成。
- 丰富的研究方法：Integrate secondary data from non-identified databases (such as EMRs, Claims, Research cohorts) with primary data from physicians and patients to build a comprehensive patient record specific to your research.在这里了解更多。
- 外部比较器研究：Provide context for single-arm trials using real world data, increase operational efficiencies and answer Regulators’ and Payors’ requirements with confidence.
- 扩展研究：通过使患者和研究人员参与审判后，实现其他研究目标。提高效率并捕获长期患者的结局，以了解您的药物的长期安全性和有效性。
- Pragmatic Trials:生成真实的证据，以评估在现实生活中的随机干预措施的有效性，帮助您回答监管机构和付款人对产品的问题。
加速招聘
通过与现有的现实世界数据源建立联系，我们可以更轻松地找到合适的患者并迅速招募。
监管知识
One potential challenge of new study designs is regulatory acceptance. IQVIA brings a history of EMA-accepted Drug Utilization Studies (DUS) in multiple therapy areas and geographies and extensive experience working with the FDA, ENCePP, EUnetHTA , MHRA.
Current working knowledge helps ensure that your studies meet regulatory standards. As active partners and participants with OMOP, ENCePP, EUnetHTA, IMI, the Department of Health and Human Services and others, IQVIA is committed to remaining current for the benefit of our customers.
Current working knowledge helps ensure that your studies meet regulatory standards. As active partners and participants with OMOP, ENCePP, EUnetHTA, IMI, the Department of Health and Human Services and others, IQVIA is committed to remaining current for the benefit of our customers.
学到更多